Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis
- PMID: 36687420
- PMCID: PMC9850223
- DOI: 10.3389/fmed.2022.1125836
Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis
Abstract
[This corrects the article DOI: 10.3389/fmed.2022.859330.].
Keywords: JAK inhibitor; baricitinib; digital ulcers; skin fibrosis; systemic sclerosis.
Copyright © 2023 Hou, Su, Han, Xue, Chen, Chen, Wang, Yang, Liang and Ji.
Erratum for
-
JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis.Front Med (Lausanne). 2022 Jun 6;9:859330. doi: 10.3389/fmed.2022.859330. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35733864 Free PMC article.
Similar articles
-
JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis.Front Med (Lausanne). 2022 Jun 6;9:859330. doi: 10.3389/fmed.2022.859330. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35733864 Free PMC article.
-
Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report.Case Rep Rheumatol. 2019 Jul 9;2019:5293981. doi: 10.1155/2019/5293981. eCollection 2019. Case Rep Rheumatol. 2019. PMID: 31360575 Free PMC article.
-
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Lancet. 2018. PMID: 30043749 Clinical Trial.
-
Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.Expert Rev Clin Immunol. 2019 Jul;15(7):693-700. doi: 10.1080/1744666X.2019.1608821. Epub 2019 Apr 25. Expert Rev Clin Immunol. 2019. PMID: 30987474 Review.
-
Application of Baricitinib in Dermatology.J Inflamm Res. 2022 Mar 18;15:1935-1941. doi: 10.2147/JIR.S356316. eCollection 2022. J Inflamm Res. 2022. PMID: 35330989 Free PMC article. Review.
Cited by
-
Baricitinib represses the myocardial fibrosis via blocking JAK/STAT and TGF-β1 pathways in vivo and in vitro.BMC Cardiovasc Disord. 2025 Jan 31;25(1):65. doi: 10.1186/s12872-025-04517-x. BMC Cardiovasc Disord. 2025. PMID: 39891042 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous